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Abstract 
Purpose: To explore the effects of tanshinone IIA (T-IIA) on Dianeal-N PD-4 (PDF)-induced expression 
of fibrogenic cytokines in human peritoneal mesothelial cells (HPMCs), and to elucidate the 
mechanisms of action involved. 
Methods: Seven groups of HPMCs were used in the study: control group, PDF group, T-IIA group, 
LY364947 group, and 2 transforming growth factor-β (TGF-β) groups (TGF-β+ 50 μM T-IIA and TGF-β+ 
100 μM T- IIA). The expression levels of mRNA and protein of TGF-β, smad2, smad7, α-smooth muscle 
actin(α-SMA), fibronectin, collagen І, E-cadherin, N-cadherin, matrix metalloprotein-2(MMP-2), and 
MMP-9 in the various groups were determined by reverse transcription-polymerase chain reaction (RT-
PCR) and Western blotting as appropriate. 
Results: The expressions of α-SMA, fibronectin, collagen І, TGF-β and smad2 were significantly up-
regulated in HPMCs by PDF treatment, but smad7 was down-regulated, relative to the control group (p 
< 0.01).These PDF-induced effects were reversed by T-IIA (p < 0.05). Inhibition of TGF-β/smad 
pathway by LY364947 treatment led to significant decrease in the expressions of fibrosis-related 
proteins, when compared with PDF group (p < 0.05). TGF-β treatment also produced numerous spindle-
shaped HPMCs characteristic of epithelial-mesenchymal transition (EMT). However, this morphological 
transition was alleviated, and the expression levels of EMT-related proteins were significantly down-
regulated by exposure to the two doses of T-IIA (p < 0.05).  
Conclusion: Tanshinone IIA inhibits EMT in HPMCs by regulating TGF-β/smad pathway, thus 
mitigating peritoneal fibrosis. Therefore, T-IIA has promising potential as a new drug for the treatment of 
peritoneal dialysis (PD)-induced fibrosis. 
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 End-stage renal disease (ESRD) is a major 
public health issue all over the world [1]. 
Peritoneal dialysis (PD) is a widely used renal 
replacement treatments for ESRD. However, 
about 3 – 36 % of PD patients have experienced 
peritoneal ultrafiltration failure within 1 - 4 y after 
PD [2]. The major cause of peritoneal 
ultrafiltration failure is peritoneal fibrosis: 
-----------------------------------------------------------------------------------------------------------------------------------------------------
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repeated PD increases the risk of peritoneal 
fibrosis, resulting in peritoneal ultrafiltration 
failure which eventually forces patients to 
abandon the treatment [2,3]. Therefore, 
peritoneal fibrosis is a critical constraint in the 
development of PD. Thus, it is important to 
investigate the mechanism of peritoneal fibrosis 
and develop new therapeutic targets for the 
disease as a way of enhancing the development 
of PD. 
 
Peritoneal fibrosis is characterized by absence of 
peritoneal mesothelial cell layer and increase in 
mesenchymal layer [3,4]. Factors such as 
peritoneal dialysis fluid biocompatibility, 
peritonitis, and cytokines are implicated in the 
etiology of peritoneal fibrosis [3,4]. Multiple 
mechanisms contribute to the incidence and 
progression of the disease. These include 
fibrosis-promoting factor, oxidative stress and 
peritoneal EMT of mesothelial cells [3,4]. 
However, EMT is the main mechanism involved 
in peritoneal fibrosis [4]. 
 
EMT is a biological process in which mature 
epithelial cells are transformed into cells with 
mesenchymal phenotype [5]. During this 
process, epithelial cells usually lose their 
adhesion ability and rearrange their cytoskeleton, 
leading to a decline in peritoneal function [5]. It 
has been reported that many signal transduction 
pathways may lead to EMT in peritoneal 
mesothelial cells. These are ROS / MMP-9 
pathway [6], PI3k / AKT pathway [7], and 
transforming growth factor (TGF-β) signaling 
pathway [8]. Accumulating evidence have 
consistently indicated that TGF-β1 is the marker 
that induces EMT in peritoneal mesothelial cells, 
and that the TGF-β1 / smad3 signaling pathway 
is a key factor involved in EMT [8-10]. Although a 
lot of studies have been carried out on peritoneal 
mesothelial cell EMT, the mechanisms involved 
in the process have not been fully elucidated. It 
has been reported that T-IIA, an active 
component of the Chinese herb Danshen, 
inhibits fibrosis in various tissues [11-13]. In 
previous animal studies, it was shown that T-IIA 
significantly inhibited high glucose-based, PDF-
induced peritoneal fibrosis [14]. The present 
study was aimed at investigating the effects of T-
IIA on PDF-induced expression of fibrogenic 





Chemicals and reagents 
 
Tanshinone IIA (Figure 1) was obtained from 
Carephar (Nanjing, China). Dianeal-n PD-4 with 
4.25 % glucose (PDF) was obtained from Baxter 
(Guangzhou, China). All the antibodies were 
purchased from Abcam (USA). Normal Australian 
fetal bovine serum (FBS), high-glucose DMEM 
medium, and 0.25 % EDTA-Trypsin were 
purchased from GIBCO (NY, USA). Trizol 
reagent was product of Invitrogen (California, 
USA), and real-time PCR reaction kit was from 








Human peritoneal mesothelial cells (HPMCs) 
were obtained from ATCC (VA, USA). The cells 
were cultured in a high-glucose DMEM medium 
containing 10 % FBS in a 5 % CO2 humidified 
incubator at 37 °C. The third-generation cells 
were used for subsequent experiments. When 
grown to sub-fusion state, the cells were 
incubated in serum-free culture medium for 24 h 
to synchronize cell growth, and then assigned to 
7 groups: the control group, PDF group, PDF+50 
μM T-IIA group, PDF + 5 μM TGF-β inhibitor 
(LY364947) group, 5 ng/mL TGF-β group, 5 
ng/mL TGF-β + 50 μM T - IIA group and 5 ng/mL 
TGF-β + 100 μM T - IIA group. The cells were 
then used for the following experiments after 
another 72 h culture in their respective treatment 
states. 
 
Real-time quantitative PCR 
 
Trizol reagent (Invitrogen, USA) was used to 
extract the total RNA from the cells, cDNA was 
synthesized using commercially available 
reverse transcription kit (Takara, China). RNA 
(1ug) was reverse-transcribed into cDNA, which 
was then subjected to PCR amplification. The 
PCR reactions were performed using ABI 7500 
Real-Time PCR System (ABI, USA). The 
amplification conditions were as follows: 95 °C 
for 30 s; 95 °C for 5 s, 60 °C for 34 s (40 cycles). 
The gene specific primer pairs for TGF-β, 
smad2, smad7, α-SMA, fibronectin, collagen І, E-
cadherin, N-cadherin, MMP-2, MMP-9, and 
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GADPH are listed in Table 1. All the mRNA 
expression levels were normalized to that of 
GADPH using the 2∆∆Ct method. All the 
determinations were conducted in triplicate. 
 
Western blot analysis 
 
The cells were harvested and lysed in RIPA 
buffer (Sigma-Aldrich, USA). BCA assay 
(Thermo Fisher Scientific, USA) was applied to 
determine the protein concentrations. Extracted 
total protein (30μg) was separated by 10 % SDS-
PAGE, electro-transferred onto a polyvinylidene 
fluoride (PVDF) membrane, and sealed with skim 
milk at 4 oC overnight. Then, the membrane was 
incubated with primary antibodies (Abcam, USA) 
against TGF-β, smad2, smad7, α-SMA, 
fibronectin, collagen І, E-cadherin, N-cadherin, 
MMP-2, MMP-9, tubulin, and GADPH for 4 hours 
at room temperature. The membrane was 
washed 3 times with Tris-buffered saline 
containing 0.1 % Tween-20 (TBS-T), and 
incubated with horseradish peroxidase (HRP) 
conjugated to goat anti-mouse secondary 
antibody (1:2000; Abcam, USA) at room 
temperature for two hours. It was then washed 
thrice in TBS-T. Tubulin and β-actin were used 
as internal references. Bands were developed 
using an electro-chemiluminescence (ECL) kit 
(Thermo Fisher Scientific, USA). 
 
Statistical analysis   
 
Analyses were performed using SPSS v.13.0 
(SPSS Inc., Chicago, IL). The results are 
presented as mean ± SD. Differences between 
groups were assessed by one-way ANOVA. 





T-IIA exerted protective effect against PDF-
induced fibrosis in HPMCs   
 
To study the effect of T-IIA on PDF-induced 
fibrosis, the expression levels of fibrosis-related 
proteins in HPMCs were determined. RT-PCR 
analysis (Figure 2 A) showed that the mRNA 
expression levels of α-SMA, fibronectin, and 
collagen І were significantly up-regulated in 
HPMCs when treated with PDF (p < 0.01, 
relative to the control group). Consistent with the 
mRNA expression, the protein expression levels 
of these proteins were also significantly up-
regulated when compared with the control group 
(p < 0.05; Figures 2B and Figure 2C). Moreover, 
in the PDF+IIA group, T-IIA treatment 
significantly decreased the expressions of α-
SMA, fibronectin, and collagen І with respect to 
mRNA (Figure 2A) and protein (Figures 2B and 
Figure 2C). This indicates that T-IIA exerts 
protective effect on the HPMCS. Interestingly, 
PDF treatment significantly up-regulated the 
expressions of TGF-β and smad2, and down-
regulated the expression of smad7 (p < 0.01, 
relative to the control group; Figure 2). These 
effects brought about by PDF were reversed by 
T-IIA treatment (p < 0.05, when compared to the 
PDF group; Figure 2). 
 
T-IIA treatment inhibited fibrosis in HPMCs by 
regulation of the TGF-β/smad pathway 
 
As shown in Figure 3, LY364947 treatment 
significantly inhibited the expression of TGF-β (p 
< 0.05, versus the PDF group), and down-
regulated the expressions of smad2, and smad7. 
  
 
Table 1: Primers used for real-time PCR analysis of mRNA 
 
Target gene Primer sequence 
GAPDH Forward (5’-3’) TGAACGGGAAGCTCACTGG Reverse (5’-3’) TCCACCACCCTGTTGCTGTA 
α-SMA Forward (5’-3’) ATTGTGCACACCATTGGGA Reverse (5’-3’) GATGGTTGTGTAGGGGTTGG 
E-cadherin Forward (5’-3’) GATGGTTGTGTAGGGGTTGG Reverse (5’-3’) AGGCTGTGCCTTCCTACAGA 
FN Forward (5’-3’) CAGTGGGAGACCTCGAGAAG  Reverse (5’-3’) GTCCCTCGGAACATCAGAAA 
Collagen 1 Forward (5’-3’) TCCTGCGTGTACCCCACTCA Reverse (5’-3’) ACCAGACATGCCTCTTGTCCTT 
TGF-β1 Forward (5’-3’) CACGTGGAGCTGTGCCAGAA Reverse (5’-3’) GAACCCGTTGATGTCCACTT 
MMP-2     Forward (5’-3’) ATGACAGCTGCACCACTGAG Reverse (5’-3’) ATTTGTTGCCCAGGAAAGTG 
MMP-9     Forward (5’-3’) AGGGCACATCCTATGACAGC     Reverse (5’-3’) ATTTGTTGCCCAGGAAAGTG 
 




Figure 2: Protective effects of T-IIA against PDF-induced fibrosis in HPMCs. (A) mRNA and (B) protein 
expression levels of fibrogenic cytokines and TGF-β/smad pathway-related proteins in HPMCs in different 
treatment groups determined by RT-PCR and Western blot. (C) Quantitative analysis of the developed protein 
bands. *, p < 0.05, **, p < 0.01, versus the control group; #p < 0.05, ##p < 0.01, versus PDF group 
 
Due to the inhibition of TGF-β/smad pathway, in 
expression of mRNA (Figure 3A) and protein 
(Figures 3B & 3C) levels, the expressions of the 
fibrosis-related proteins were significantly 
decreased when compared with the PDF group 
(p < 0.05, Figure 3). 
 
T-IIA treatment inhibited EMT of HPMCs  
 
Characteristically, mesenchymal cells have 
highly proliferative ability, with spindle-shape and 
well-spread morphology [15]. As shown in Figure 
3A, TGF-β treatment led to appearance of 
numerous spindle-shaped HPMCs, which 
indicates that the HPMCs underwent EMT. 
However, this morphological transition was 
alleviated by exposure of the HPMCs to different 
concentrations of T-IIA. Moreover, RT-PCR 
(Figure 4B) and Western blot (Figures 4C and 
Figure 4D) results showed that the expressions 
of N-cadherin, MMP-2, and MMP-9 were 
significantly decreased, compared with the TGF-
β group, while E-cadherin expression was 
significantly up-regulated (p < 0.05). These 
results indicate that T- IIA treatment inhibited the 




Peritoneal dialysis (PD) is an important 
alternative treatment for ESRD. In PD, the 
peritoneum is used as a semipermeable 
membrane to remove metabolic wastes and 
excess water in the body according to dispersion 
and penetration principles [2,3]. It has always 
been thought that the activation of fibroblasts 
inherent in peritoneal tissue and the infiltration of 
inflammatory cells are the most important factors 
that cause structural and functional changes in 
peritoneal tissue [16]. However, recent studies 
have found that the long-term stimulation by non-
biocompatible peritoneal dialysis solution can 
lead to the EMT of peritoneal mesothelial cells 
[2,3,16]. EMT is a highly regulated process that 
has a vital role in embryonic development, tumor 
formation and fibrosis in some chronic 
inflammatory diseases [3,4]. Peritoneal 
mesothelial cell EMT is one of the key factors 
responsible for gradual decreases in peritoneal 
functions in peritoneal dialysis patients [3,4]. 




TGF-β1 is an important fibrosis-promoting factor 
in several tissues and organs, including 
peritoneal tissue; its role is to  phosphorylate the 
signaling protein smad2 /3 [17]. Smad protein is 
a downstream signal regulatory protein of the 
TGF-β1 receptor complex, and it transfers TGF-β 
signal from the cell membrane to the nucleus 
[17,18]. Many of the biological function of TGF-β 
are mediated by smads signaling pathway, and 
smad2 / 3 falls into the type of receptor-
modulating smads, the phosphorylation of which 
acts as the most important step and sign of smad 
pathway activation [17,18]. Therefore, the 
expression level of intracellular p-smad2 /3 is an 
index of the degree of activation of the pathway.  
 
Excessive expression of smad7 inhibits the 
binding of smad2 and smad3 molecules to 
activated type I receptors as well as their 
phosphorylation, thereby exerting a negative 
regulating effect on TGF-β signal transduction 
[19]. Down-regulation of the expression of smad7 
protein is associated with fibrosis, while the up-
regulation of its expression reverses the 
occurrence and progression of fibrosis [17,19]. 
This is consistent with the results obtained in this 
study. PDF treatment significantly up-regulated 
the expression of TGF-β and smad2, and down-
regulated the expression of smad7, but this trend 
was reversed by T-IIA. This finding indicates that 
T-IIA inhibits fibrosis in HPMCs by regulation of 
the TGF-β/smad pathway. 
 
TGF-β1 is also a key regulator of EMT [8]. It can 
induce transition in HPMCs in vitro and in vivo 
[20,21]. The transition of epithelial cells to 
mesenchymal cells involves loosening of 
epithelial cells, loss of microvilli, decreased 
expressions of epithelial cell markers like E-
cadherin and Z0-1, and increased expression of 
fibroblast markers (e.g. a-SMA).  It also involves 
cytoskeleton re-modelling, intercellular matrix 
degradation and changes in adhesion between 
the cells and matrix, resulting in enhanced ability 
of cell migration and invasion [5]. 
 
 
Figure 3: Inhibitory effect of T-IIA on fibrosis in HPMCs via regulating the TGF-β/smad pathway. (A) mRNA and 
(B) protein expression levels of fibrogenic cytokines and TGF-β/smad pathway-related proteins in HPMCs in 
different treatment groups determined by RT-PCR and Western blot. (C) Quantitative analysis of the developed 
protein bands. *p < 0.05, **p < 0.01, versus the control group; #p < 0.05, ##p < 0.01, versus PDF group 
 





Figure 4: Inhibitory effect of T-IIA on EMT in HPMCs. (A) Morphology of HPMCs under different treatments. (B) 
mRNA and (C) protein expression levels of EMT-related proteins (E-cadherin, N-cadherin, MMP-2, and MMP-9) 
in HPMCs in different treatment groups determined by RT-PCR and Western blot. (D) Quantitative analysis of the 
developed protein bands; *p < 0.05, **p < 0.01, versus the control group; #p < 0.05, ##p < 0.01, versus TGF-β 
group. 
 
Yanez-Mo et al [22]  discovered that peritoneal 
mesothelial cells exhibited EMT shortly after PD, 
which manifested in loss of epithelial cell 
morphology, down-regulated expression of 
cytokeratin and E-cadherin, and up-regulated 
expression of a2 integrin. They also found that 
peritoneal mesothelial cells cultured in vitro in PD 
effluent showed many morphological changes, 
including epithelial cell-likeness, fibroblast-
likeness and a mixture of both features.  
 
The intercellular adhesion molecule-1 (ICAM-1) 
was highly expressed in these different forms of 
cells, suggesting that the fibroblast-like cells 
were derived from peritoneal mesothelial cells. A 
study of 35 patients treated with standard PD for 
2 years, found that 74 % of them experienced 
mesothelial cell layer loss, 46 % experienced 
peritoneal fibrosis, and 17 % had evidence of in 
situ EMT [23].  Studies have shown that TGF-β1 
mediates EMT through Smad pathway [17,19]. 
The target gene regulating TGF-β1 in EMT is 
dependent on the transcriptional regulation of 
smad2 and smad3, while smad7 interdicts its 
combination with TGF-β type I receptor by 
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inhibiting the phosphorylation of activated Smad 
protein [17,19].  
 
Overexpression of TGF-β1 in rodents can cause 
EMT of peritoneal mesothelial cells [24]. This has 
been demonstrated by using adenovirus to 
introduce TGF-β1 into the peritoneum so as to 
overexpress TGF-β1, thereby inducing EMT of 
HPMCs and peritoneal fibrosis [25]. Bone 
morphogenetic protein reverses HPMC transition 
by inhibiting smad2/3 and MAPKs resulting from 
hyperglycemia-activated TGF-β1. In the present 
study, it was discovered that PDF significantly 
enhanced the expressions of mRNAs for TGF-β1 
and smad2, and suppressed the mRNA 
expression of smad7. However, the addition of T-
II A led to significant down-regulation of the 
expression of mRNAs for TGF-β1 and smad2, 
and significant up-regulation of the expression of 
smad7 mRNA. This clearly suggests that T-II A 
inhibits the TGF-β1 signal transduction pathway; 
and by implication, it also inhibits EMT. The 
results of this study indicate that TGF-β1/smad3 
signaling transduction pathway plays an 
important role in EMT during peritoneal fibrosis, 
and that T-II A has promising potential as an 




T-IIA treatment inhibits EMT of HPMCs via 
regulation of TGF-β/smad pathway, thereby 
preventing PD-induced peritoneal fibrosis. Thus 
T-IIA offers tremendous potential for the 
development of a new drug for the treatment of 
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